The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
Oncology products took center stage last week, thanks to submissions for Blueprint Medicines Corp.’s targeted therapy pralsetinib, Y-mAbs’ antibody therapeutic naxitamab, bluebird bio Inc. and Bristol-Myers Squibb Co.’s CAR-T immunotherapy idecabtagene vicleucel, and, for the second time, Aveo Pharmaceuticals Inc.’s targeted therapy tivozanib.
Zealand Pharma AS and Rhythm Pharmaceuticals Inc. also announced new submissions, for rescue pen to treat hypoglycemia in...
A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
New marketing authorization applications filed with the European Medicines Agency's human medicines committee (the CHMP) for review under the EU's centralized procedure. Updated monthly.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
A real-world evidence study also does not meet the regulatory standard for an adequate and well-controlled clinical investigation, the agency said. The FDA should allow the accelerated approval drug to remain available like other treatments that failed their confirmatory trials, Intercept said.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
